Related Experiment Video
Updated: Jun 12, 2026
A Microscopic 2,3,5-Triphenyltetrazolium Chloride Assay for Accurate and Reliable Analysis of Myocardial Injury
Published on: November 28, 2025
A timely diagnosis of myocardial infarction
J A Shand1, I B Menown, D J McEneaney
1Craigavon Cardiac Centre, Southern Trust, Northern Ireland, UK.
Insights
New biomarkers and sensitive troponin assays aim to speed up acute myocardial infarction diagnosis. Early detection of heart attacks is crucial for timely treatment and efficient patient care.
Area of Science:
- Cardiology
- Biomarker Discovery
Background:
- Current troponin assays for acute myocardial infarction (AMI) diagnosis have a detection lag of 6-9 hours post-symptom onset.
- This delay can lead to misdiagnosis, delayed treatment, and inefficient healthcare resource allocation for patients with acute chest pain.
Purpose of the Study:
- To explore novel biomarkers and highly sensitive troponin assays for early detection and exclusion of AMI.
- To address the limitations of existing diagnostic methods for myocardial infarction.
Main Methods:
- Review of research on alternative biomarkers including myoglobin, heart-type fatty acid binding protein, glycogen phosphorylase BB, D-dimer, and matrix metalloproteinase 9.
- Evaluation of recent advancements in highly sensitive troponin assays.
Main Results:
- Highly sensitive troponin assays demonstrate over 95% sensitivity for early AMI detection.
- These novel assays may come with reduced specificity, necessitating careful interpretation.
Conclusions:
- Novel biomarkers and advanced troponin assays show promise for earlier myocardial infarction diagnosis.
- Optimal strategies for integrating these new tools with clinical assessment are still under investigation and require further research.
Abstract:
The diagnosis of acute myocardial infarction currently rests on the measurement of troponin, a biomarker of myocardial necrosis. Unfortunately, the current generation troponin assays detect troponin only 6-9 h after symptom onset. This can lead to a delay in diagnosis and also excessive resource utilization when triaging patients who, ultimately, have noncardiac causes of acute chest pain. For these reasons, there has been extensive research interest in biomarkers that can detect and rule out myocardial infarction early after symptom onset. These include markers of myocardial injury, such as myoglobin, heart-type fatty acid binding protein, glycogen phosphorylase BB; hemostatic markers, such as D-dimer; and finally, inflammatory markers, such as matrix metalloproteinase 9. Recently, highly sensitive troponin assays have reported an early sensitivity for myocardial infarction of greater than 95%, although at a cost of reduced specificity. The optimal strategy with which to use these novel biomarkers and highly sensitive troponins has yet to be determined, and interpretation of their results in light of thorough clinical assessment remains essential.
More Related Videos
Related Concept Videos
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:30Acute Coronary Syndrome I: Introduction
01:27Myocarditis II: Clinical Features and Diagnostic Tests
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:30Introduction Cardiac Emergencies